Literature DB >> 23775959

Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation.

Shahryar Kiaii1, Andrew J Clear, Alan G Ramsay, Derek Davies, Ajanthah Sangaralingam, Abigail Lee, Maria Calaminici, Donna S Neuberg, John G Gribben.   

Abstract

PURPOSE: Previous studies have demonstrated the prognostic importance of the immune microenvironment in follicular lymphoma (FL). To investigate the molecular mechanisms during which tumor-infiltrating T cells (TILs) are altered in the FL microenvironment, we studied highly purified CD4 and CD8 TILs from lymph node biopsies at diagnosis in treatment-naive patients with FL compared with reactive tonsils and the peripheral blood of healthy donors. PATIENTS AND METHODS: Gene expression profiling of highly purified CD4 and CD8 TILs was performed on the Affymetrix platform. Diagnostic tissue microarrays from an independent patient set (n = 172) were used to verify protein expression and analyze any impact of TIL-expressed genes on outcome. Time-lapse imaging was used to assess T-cell motility.
RESULTS: The most upregulated genes in both CD4 and CD8 TILs were PMCH, ETV1, and TNFRSF9. PMCH is not expressed in peripheral blood T cells, but expression is highly induced on culture with FL. Both CD4 and CD8 TILs from patients with FL have significantly impaired motility compared with those of healthy TILs from reactive tonsils and this can be induced on healthy T cells by FL cells. During multivariate analysis, a model incorporating the number and location of T cells expressing PMCH, NAMPT, and ETV1 showed prognostic significance for overall survival and for time to transformation.
CONCLUSION: We showed altered gene expression in TILs in FL and demonstrated that altering the immune microenvironment in FL affects overall survival and time to transformation in this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775959      PMCID: PMC3709054          DOI: 10.1200/JCO.2012.44.2137

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  36 in total

Review 1.  Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors.

Authors:  Daphne de Jong
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

Review 2.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

Review 3.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.

Authors:  D G Altman; B Lausen; W Sauerbrei; M Schumacher
Journal:  J Natl Cancer Inst       Date:  1994-06-01       Impact factor: 13.506

4.  The rat melanin-concentrating hormone messenger ribonucleic acid encodes multiple putative neuropeptides coexpressed in the dorsolateral hypothalamus.

Authors:  J L Nahon; F Presse; J C Bittencourt; P E Sawchenko; W Vale
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

5.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Authors:  Pedro Farinha; Hamid Masoudi; Brian F Skinnider; Karey Shumansky; John J Spinelli; Karamjit Gill; Richard Klasa; Nicolas Voss; Joseph M Connors; Randy D Gascoyne
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

6.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Authors:  Alan G Ramsay; Andrew J Clear; Rewas Fatah; John G Gribben
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

7.  How I treat indolent lymphoma.

Authors:  John G Gribben
Journal:  Blood       Date:  2007-02-20       Impact factor: 22.113

8.  Pmch expression during early development is critical for normal energy homeostasis.

Authors:  Joram D Mul; Chun-Xia Yi; Sjoerd A A van den Berg; Marieke Ruiter; Pim W Toonen; Martine C J van der Elst; Peter J Voshol; Bart A Ellenbroek; Andries Kalsbeek; Susanne E la Fleur; Edwin Cuppen
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-24       Impact factor: 4.310

9.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

Authors:  Alan G Ramsay; Andrew J Clear; Gavin Kelly; Rewas Fatah; Janet Matthews; Finlay Macdougall; T Andrew Lister; Abigail M Lee; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

10.  Human Th2 cells selectively express the orexigenic peptide, pro-melanin-concentrating hormone.

Authors:  Hilary Sandig; Joanne McDonald; Jane Gilmour; Matthew Arno; Tak H Lee; David J Cousins
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-18       Impact factor: 11.205

View more
  39 in total

Review 1.  Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.

Authors:  Patrick M Reagan; Jonathan W Friedberg
Journal:  Curr Treat Options Oncol       Date:  2015-07

Review 2.  The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Authors:  K H Shain; W S Dalton; J Tao
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

3.  Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma.

Authors:  Falko Fend; Leticia Quintanilla-Martínez
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 4.  Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Authors:  Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

Review 5.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

Review 6.  Role of the microenvironment across histological subtypes of NHL.

Authors:  Karin Tarte
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Indolent lymphomas: pushing the pace with novel agents.

Authors:  Caron A Jacobson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Authors:  Veronika Bachanova; Dhifaf Sarhan; Todd E DeFor; Sarah Cooley; Angela Panoskaltsis-Mortari; Bruce R Blazar; Julie M Curtsinger; Linda Burns; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2017-12-07       Impact factor: 6.968

9.  In silico analysis identifies CRISP3 as a potential peripheral blood biomarker for multiple myeloma: From data modeling to validation with RT-PCR.

Authors:  Dong Leng; Ran Miao; Xiaoxi Huang; Ying Wang
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

Review 10.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.